




PCT/EP03/02365

10/6936 

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely as the company to certain additional company law rules.



Signed


Dated 2 January 2003

BEST AVAILABLE COPY

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
(Rule 16)



The
Patent
Office

11 MAR 2002 11:10-1 000524
F01 7700 0205-020537.4

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1.	Your reference	4-32388P1		
2.	Patent application number (The Patent Office will fill in this part)	0205537.4		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND 7125 487005		
	Patent ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	SWITZERLAND		
4.	Title of invention	Organic compounds		
5.	Name of your agent (If you have one)	B.A. YORKE & CO. CHARTERED PATENT AGENTS COOMB HOUSE, 7 ST. JOHN'S ROAD ISLEWORTH MIDDLESEX TW7 6NH		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)			
	Patents ADP number (if you know it)	1800001		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 30

Claim(s) 5

Abstract

Drawing(s)

-
10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) ONE

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co

B.A. Yorke & Co.

08 March 2002

-
12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham

020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

This invention relates to organic compounds, in particular to pharmaceutical compositions for use in combination with radiotherapy for the treatment of cancer.


Carcinoma is by far the most common type of cancer it accounts for about 80% of all cases of cancer. The severity of a carcinoma can vary widely with pancreatic cancer being one of the most aggressive and lethal neoplasms with an extremely low 5-year survival rate; Landis, S. et al (CA Cancer J. Clin., 49: 8-31, 1999) and Niederhuber, J. E. et al (Cancer, 76:1671-1677, 1995). Because most patients with pancreatic cancer miss the opportunity for complete surgical resection at the time of diagnosis, radiotherapy remains as a major component of treatment modalities for controlling tumor progression. Malignant progression of pancreatic cancer depends not only on rapid proliferation of tumor cells but also on other biological behaviours including motility, invasiveness, and metastatic potential. More generally radiotherapy remains a major therapeutic option for patients with various other types of advanced cancer. Radiotherapy besides having the desired effect also has an effect on malignant biological behaviours for example it has now been found that while it significantly inhibits cell proliferation and migration irradiation may enhance the invasive potential in pancreatic cancer cells.

Radiotherapy treatment for cancer which can be treated using radiotherapy is a very valuable tool although there are risks including the promotion of the cancer. A treatment that has all the benefits of the current radiotherapy but without or with a much reduced risk of promoting the development of the cancer would be highly beneficial.

We have now found that certain matrix metalloproteinase inhibitors are effective when used in combination with radiotherapy for the treatment of cancer which can be treated


with radiotherapy for example cancers of the brain, breast, larynx, pancreas, skin, tongue, uterine cervix also leukaemia and lymphoma.

Accordingly the invention provides a method of treating cancer in a subject in need of such treatment which comprises administering to the subject an effective amount of a matrix metalloproteinase inhibitor of the formula I in combination with radiotherapy



(i) Wherein

A represents substituent of formula II or III;



wherein


R represents hydrogen, lower alkyl, aryl-lower alkyl, aryl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, (oxa or thia)-cycloalkyl, [(oxa or thia)-cycloalkyl]-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower

alkyl, (N-lower alkyl-piperazino or N-aryl- lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl;

R₃ represents aryl that may be unsubstituted or substituted by R₄ and R₅;

R₄ or R₅ represents independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano, oxy-C₂-C₃-alkylene, 1- or 2-naphthyl; or R₄ and R₅ together on adjacent carbon atoms represent lower alkylenedioxy;

n represents an integer from 1 to 5;



Formula III


Wherein

R₆ is C₃₋₁₂ alkyl, C₃₋₁₂ alkenyl, C₃₋₇(optionally hydroxy-, C₁₋₆ alkoxy-, amino-, or C₁₋₆ alkylamino- substituted) cycloalkyl, C₅₋₁₄ aryl, or C₅₋₁₄ aryl(C₁₋₆ alkyl), wherein aryl groups are optionally substituted by hydroxy-, C₁₋₆ alkyl-, C₁₋₆ alkoxy-, amino-, halo- or cyano-;

R₇ is C₁₋₁₀ (optionally hydroxy- or C₁₋₆alkoxy- amino-, C₁₋₆ alkylamino-, thiol-, C₁₋₆ alkylmercapto- or protected hydroxy-, amino- or thiol- substituted) alkyl, C₆₋₁₄ (optionally hydroxy-, C₆₋₁₄aryloxy-, or C₁₋₆alkoxy-, amino-, C₁₋₆ alkylamino-, halo-, or cyano-substituted)aryl, or indolylmethyl;

R₈ is methyl, pyridyl, or a substituent of formula X-Y- wherein X is morpholino, pyridyl or aryl, and Y is C₁₋₁₂alkylene in which up to four of the methylene (-CH₂-) units are optionally replaced with -CO-, -NH-, -SO₂- or -O-;

R₁ is hydrogen, lower alkyl, aryl, aryl-lower alkyl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, cycloalkyl-cycloalkyl, aryl-lower alkyl-lower cycloalkyl, lower alkyl-cycloalkyl, lower alkoxy-lower alkyl-cycloalkyl, aryl-cycloalkyl, cycloalkyl-lower alkyl-cycloalkyl, halo-lower alkyl-cycloalkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl, N-lower alkylpiperidyl or a substituent of formula IV



Formula IV

wherein

z is 1, 2, 3 or 4;

m is 0, 1, 2 or 3;

each R₉ is

independently H, C₁₋₁₀ (optionally hydroxy-, C₁₋₆ alkoxy-, amino-, C₁₋₆ alkylamino-, thiol-, C₁₋₆ alkylmercapto- or protected hydroxy, amino or thiol substituted) alkyl, C₂₋₆ alkenyl, C₆₋₁₄(optionally hydroxy-, C₁₋₆ alkoxy-, amino-, C₁₋₆ alkylamino-, halo- or cyano-substituted) aryl, or C₆₋₁₄ (aryl) C₁₋₆alkyl;

D is hydrogen, C₁₋₁₀ alkyl, C₆₋₁₄ aryl, C₆₋₁₄ aryl(C₁₋₆ alkyl), (C₆₋₁₄ aryl)carbonyl, or (C₁₋₁₀ alkyl)carbonyl;

R₂ is hydrogen or lower alkyl,

(ii) or wherein

R (of formula II under (a)) and R₁ together with the chain to which they are attached form a 1,2,3,4-tetrahydro-isoquinoline, piperidine, oxazolidine, thiazolidine or pyrrolidine ring, each unsubstituted or substituted by lower alkyl; and

R₃ and R₂ have meaning as defined under (i);

(iii) or wherein

R₁ and R₂ together with the carbon atom to which they are attached form a ring system selected from lower cycloalkane which is unsubstituted or substituted by lower alkyl, oxa-cyclohexane, thia-cyclohexane, indane, tetralin, piperidine or piperidine substituted on nitrogen by acyl, lower alkyl, aryl-lower alkyl, (carboxy, esterified or amidated carboxy)-lower alkyl or by lower alkylsulfonyl; and

R₃ and R meaning as defined under (i);

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

Further the invention provides the use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) for the preparation of a medicament for use in combination with radiotherapy in the treatment of cancer which can be treated with radiotherapy.

In a further aspect the invention provides use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) in combination with radiotherapy for the treatment of cancer which can be treated with radiotherapy.

In yet further aspect the invention provides a matrix metalloproteinase inhibiting agent comprising a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as active ingredient for use in combination with radiotherapy for the treatment of cancer which can be treated with radiotherapy and which shows irradiation induced MMP especially MMP-2 expression.

In still yet further aspect the invention provides a package comprising a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) together with instructions for the use in combination with radiotherapy in the treatment of cancer which can be treated with radiotherapy.

The invention may be used for the treatment of any cancer which is susceptible to treatment by radiotherapy, including the treatment of solid tumours, carcinoma, adenocarcinoma. For example the invention may be used in the treatment of cancers of the brain, breast, larynx, skin, tongue, uterine cervix and also leukaemia and lymphoma, especially pancreatic cancer.

Above and elsewhere in the present description the following terms have the meanings given below:

The term "lower" referred to above and hereinafter in connection with organic radicals or compounds respectively defines a compound or radical which may be branched or unbranched with up to and including 7, preferably up to and including 4 carbon atoms.

A lower alkyl group is branched or unbranched and contains 1 to 7 carbon atoms, preferably 1-4 carbon atoms. Lower alkyl represents, for example, methyl, ethyl, propyl, butyl, isopropyl or isobutyl.

A lower alkoxy (or alkyloxy) group preferably contains 1-7 carbon atoms, advantageously 1-6 carbon atoms, and represents for example methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, preferably methoxy. Lower alkoxy includes cycloalkyloxy and cycloalkyl-lower alkyloxy.

Halogen (halo) preferably represents chloro or fluoro but may also be bromo or iodo.

Aryl represents carbocyclic or heterocyclic aryl including biaryl.

Carbocyclic aryl represents monocyclic, bicyclic or tricyclic aryl, for example phenyl or phenyl mono-, di- or tri-substituted by one, two or three radicals selected from lower alkyl, lower alkoxy, hydroxy, halogen, cyano, trifluoromethyl, lower alkylenedioxy, and oxy-C2-C3-alkylene; or 1- or 2-naphthyl. Lower lkylene is a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. methylenedioxy or ethylenedioxy. Oxy-C2-C3-alkylene is also a divalent substituent attached to two adjacent carbon atoms pf phenyl, e.g. oxyethylene or oxypropylene, An example for oxy-C2-C3-alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.

Heterocyclic aryl represents monocyclic or bicyclic heteroaryl, for example pyridyl, indolyl, quinoxaliny, quinolyl, isoquinolyl, benzothienyl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any said radical substituted, especially mono- or di-substituted, by lower alkyl or halogen. Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl represents 2- or 3-thienyl, advantageously 2-

thienyl. Quinolyl represents 2-, 3- or 4-quinolyl, advantageously 2-quinolyl. Isoquinolyl represents preferably 1-, 3- or 4-isoquinolyl. Benzopyranyl, benzothiopyranyl represent preferably 3-benzopyranyl or 3-benzothiopyranyl, respectively. Thiazolyl represents preferably 2- or 4-thiazolyl, advantageously 4-thiazolyl. Triazolyl is preferably 1-, 2- or 5-(1,2,4-triazolyl). Tetrazolyl is preferably 5-tetrazolyl. Imidazolyl is preferably 4-imidazolyl.

Biaryl is preferably carbocyclic biaryl, e.g biphenyl, namely 2, 3 or 4-biphenyl, advantageously 4-biphenyl, each optionally substituted by e.g. lower alkyl, lower alkoxy, halogen, trifluoromethyl or cyano.

Cycloalkyl represents a saturated cyclic hydrocarbon optionally substituted by lower alkyl which contains 3 to 8 ring carbons and is advantageously cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl optionally substituted as hereinbefore defined; cycloalkyl includes heterocyclyl.

Heterocyclyl represents a saturated cyclic hydrocarbon containing one or more, preferably 1 or 2, hetero atoms selected from O, N or S, and preferably from 3 to 10, more preferably 5 to 8, ring atoms; for example, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholino; all of which may be optionally substituted, for instance as hereinbefore defined.

Amino may be optionally substituted, e.g. by lower alkyl.

Aryl-lower alkyl represents preferably (carbocyclic aryl or heterocyclic aryl)-lower alkyl.

Carbocyclic aryl-lower alkyl preferably represents aryl-straight chain or -branched C₁₋₄-alkyl in which carbocyclic aryl has meaning as defined above, e.g. benzyl or phenyl-(ethyl, propyl or butyl), each unsubstituted or substituted preferably on the phenyl ring as hereinbefore defined for carbocyclic aryl above.

Heterocyclic aryl-lower alkyl represents preferably straight chain or branched heterocyclic aryl-C₁₋₇-alkyl in which heterocyclic aryl has meaning as defined above.

Cycloalkyl-lower alkyl represents e.g. (cyclopropyl- or cyclobutyl)-(methyl or ethyl).


Combination refers to every combination, of a MMP inhibitor of formula I and radiotherapy, such that there is an effect which would not be obtained if the MMP inhibitor of formula I is administered without prior, simultaneous or subsequent radiotherapy. Wherein radiotherapy can be continuous, sequential or sporadic. Or an effect which would not be obtained if there is radiotherapy without the prior, simultaneous or subsequent administration of a MMP inhibitor of formula I. Wherein administration can be continuous, sequential or sporadic

Preferably combination refers to every combination, of a MMP inhibitor of formula I and Radiotherapy, such that there is an effect on MMP expression or invasion potential which would not be obtained if

- a) The MMP inhibitor of formula I is administered without prior, simultaneous or subsequent radiotherapy. Wherein radiotherapy can be continuous, sequential or sporadic;
- b) There is radiotherapy without the prior, simultaneous or subsequent administration of a MMP inhibitor of formula I. Where in administration can be continuous, sequential or sporadic.

Preferred embodiments provide a method of treating cancer which can be treated with radiotherapy in a subject in need of such treatment which comprises radiotherapy in combination with administering to the subject an effective amount of ;

- a) Compound of formula V



wherein

R' represents aryl;

R'_1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl or halogen-lower alkyl;

R'_2 represents hydrogen or lower alkyl;


R'_4 and R'_5 represent independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R'_4 and R'_5 together on adjacent carbon atoms represent alkylenedioxy;

n' represents an integer from 1 to 5;

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.



R''₁ is a substituent of Formula IV'':



Formula IV"

wherein

z'' is 1, 2, 3 or 4, preferably 2;

m'' is 0, 1, 2 or 3;

each \mathbf{R}'' , is

independently H, C₁₋₁₀ (optionally hydroxy-, C₁₋₆ alkoxy-, amino-, C₁₋₆ alkylamino-, thiol-, C₁₋₆ alkylmercapto- or protected hydroxy, amino or thiol substituted) alkyl, C₂₋₆ alkenyl, C₆₋₁₄(optionally hydroxy-, C₁₋₆ alkoxy-, amino-, C₁₋₆ alkylamino-, halo- or cyano-substituted) aryl, or C₆₋₁₄ (aryl) C₁₋₆alkyl; preferably H, phenyl, benzyl or C₁₋₅ alkyl;

D'' is hydrogen, C₁₋₁₀ alkyl, C₆₋₁₄ aryl, C₆₋₁₄ aryl(C₁₋₆ alkyl), (C₆₋₁₄ aryl)carbonyl, or (C₁₋₁₀ alkyl)carbonyl; preferably hydrogen, C₁₋₆ alkyl (e.g., methyl or cyclohexyl), phenyl or benzyl;


R''₆ is C₃₋₁₂ alkyl, C₃₋₁₂ alkenyl, C₃₋₇(optionally hydroxy-, C₁₋₆ alkoxy-, amino-, or C₁₋₆ alkylamino- substituted) cycloalkyl, C₅₋₁₄ aryl, or C₅₋₁₄ aryl(C₁₋₆ alkyl), wherein aryl groups are optionally substituted by hydroxy-, C₁₋₆ alkyl-, C₁₋₆ alkoxy-, amino-, halo- or cyano-; preferably phenyl, 4-methylphenyl, cyclohexyl or isobutyl;

R''₇ is C₁₋₁₀ (optionally hydroxy- or C₁₋₆alkoxy- amino-, C₁₋₆ alkylamino-, thiol-, C₁₋₆ alkylmercapto- or protected hydroxy-, amino- or thiol- substituted) alkyl (e.g., *t*-butyl, or cyclohexylmethyl), C₆₋₁₄ (optionally hydroxy-, C₆₋₁₄aryloxy-, or C₁₋₆alkoxy-, amino-, C₁₋₆ alkylamino-, halo-, or cyano- substituted) aryl (e.g., benzyl, *p*-methoxybenzyl, *p*-benzyloxybenzyl), or indolylmethyl (e.g., 2-indolylmethyl); preferably benzyl or *t*-butyl;

R''₈ is methyl, pyridyl, or a substituent of formula X''-Y''- wherein X'' is morpholino, pyridyl or aryl (preferably morpholino), and Y'' is C₁₋₁₂alkylene in which up to four of the methylene (-CH₂-) units are optionally replaced with -CO-, -NH-, -SO₂- or -O-; for example methyl, 2-pyridyl, morpholinocarbonylmethyl, 5-(morpholino)pentyl, or 5-(morpholinocarbonyl)pentyl;

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

c) Compound of formula VII



(i') wherein

R''' represents hydrogen, lower alkyl, aryl-lower alkyl, aryl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, (oxa or thia)-cycloalkyl, [(oxa or thia)-cycloalkyl]-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl;

R'''₁ is hydrogen, lower alkyl, aryl, aryl-lower alkyl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl or N-lower alkylpiperidyl

R'''₂ is hydrogen or lower alkyl,

R'''₃ represents aryl which may be unsubstituted or substituted by R'''₄ and R'''₅;

R₄ or R₅ represents independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano, oxy-C2-C3-alkylene, 1- or 2-naphthyl; or R₄ and R₅ together on adjacent carbon atoms represent lower alkylendioxy;

(ii') or wherein

R''' and R'''₁ together with the chain to which they are attached form a 1,2,3,4-tetrahydro-isoquinoline, piperidine, oxazolidine, thiazolidine or pyrrolidine ring, each unsubstituted or substituted by lower alkyl; and R'''₂ and R'''₃ have meaning as defined under (a);


(iii') or wherein

R'''₁ and R'''₂ together with the carbon atom to which they are attached form a ring system selected from lowercycloalkane which is unsubstituted or substituted by lower alkyl, oxa-cyclohexane, thia-cyclohexane, indane, tetralin, piperidine or piperidine substituted on nitrogen by acyl, lower alkyl, aryl-lower alkyl, (carboxy, esterified or amidated carboxy)-lower alkyl or by lower alkylsulfonyl; and R'''₃ and R''' meaning as defined under (a);

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

Particularly preferred embodiments provide a method of treating cancer which can be treated with radiotherapy in a subject in need of such treatment which comprises radiotherapy in combination with administering to the subject an effective amount of;

a') Compound of formula V having the trans configuration with respect to the 1,4-substituents on the cyclohexane ring, particularly those of formula V'



wherein

R'_a represents aryl;

R'_{1a} represents lower alkyl, cycloalkyl, aryl-lower alkyl or lower alkoxy-lower alkyl;

R'_{2a} represents hydrogen or lower alkyl;

R'_{4a} is hydrogen, lower alkoxy or halogen;


R'_{5a} is hydrogen or lower alkoxy; or

R'_{4a} and R'_{5a} together on adjacent carbon atoms represent methylenedioxy; and

n'_a is 1-4;

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

b') Compound of Formula VI'




wherein;

(i) R''_{1a} is of formula IV''' or IV'''' (preferably formula IV''')



wherein D'' , z'' and m'' are as defined above.



wherein D'' , z'' and R''_9 are as defined above and m'' is 0, 1 or 2.

or D'' of formula IV''' is hydrogen, C_{1-6} alkyl, e.g., methyl or cyclohexyl (e.g., so that R''_{1a} of formula VI' is for example hydroxymethyl, cyclohexyloxyethoxymethyl, methoxyethoxyethoxymethyl, or hydroxyethyloxymethyl) or (C_{6-14} aryl)carbonyl, e.g. benzoyl (e.g. so that R''_1 of formula VI is for example benzoyloxymethyl, benzoyloxyethoxyethyl or benzoyloxyethoxyethoxymethyl);


(ii) R''_{6a} of formula VI' is cyclohexyl, phenyl, 4-methylphenyl or isobutyl;

(iii) R''_{7a} of formula VI' is benzyl or *t*-butyl; and

(iv) R''_{8a} of formula VI' is methyl or morpholinocarbonyl(C_{1-6})alkyl.


or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

The configuration of the Novel Compounds of formula VI' is preferably that of Formula VIa:



VIa

or of Formula VIb:




VIb

most preferably that of Formula VIa.

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

c') Compound of formula VII having R_3 represent phenyl which may be unsubstituted or substituted by R'''_4 and R'''_5 herein before defined, particularly those of the formula VII':



wherein

R''' represents hydrogen, lower alkyl, aryl-lower alkyl, aryl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, (oxa or thia)-cycloalkyl, [(oxa or thia)-cycloalkyl]-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl;

R'''_1 is hydrogen, lower alkyl, aryl, aryl-lower alkyl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino,

piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, piperidyl, N-lower alkylpiperidyl or acylamino-lower alkyl represented by R'''_{10} -CONH-lower alkyl;

R'''_2 is hydrogen;

R'''_{10} in R'''_{10} -CONH-lower alkyl is lower alkyl, aryl, di-lower alkylamino, N-lower alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, N-alkylpiperidyl, or (di-lower alkylamino, N-lower alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, pyridyl or N-lower alkylpiperidyl)- lower alkyl;

R'''_4 is hydrogen, lower alkoxy, hydroxy, aryl-lower alkoxy, lower alkylthio or aryl-lower alkylthio, lower alkyloxy-lower alkoxy, halogen, trifluoromethyl, lower alkyl, nitro or cyano;


R'''_5 is hydrogen, lower alkyl or halogen;

or R'''_4 and R'''_5 together on adjacent carbon atoms represent methylenedioxy, ethylenedioxy, oxyethylene or oxypropylene;

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

further and most preferred embodiments provide a method of treating cancer which can be treated with radiotherapy in a subject in need of such treatment which comprises administering to the subject an effective amount of a pharmaceutical composition for use in combination with radiotherapy. Wherein said pharmaceutical composition is;

a") compound of formula VII"



Where in;

R''' represents lower alkyl, aryl, trifluoromethyl, cycloalkyl, (oxa or thia)-cycloalkyl;

R'''₁ is hydrogen, lower alkyl, aryl, aryl-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, di-lower alkylamino-lower alkyl, (N-lower alkyl-piperazino, morpholino, thiomorpholino, piperidino, pyrrolidino)-lower alkyl or R'''₁₀-CONH-lower alkyl;

R'''₁₀ in R'''₁₀-CONH-lower alkyl is lower alkyl, aryl, di-lower alkylamino, N-lower alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, N-alkylpiperidyl, or (di-lower alkylamino, N-lower alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino or N-lower alkylpiperidyl)- lower alkyl;

R'''₄ is hydrogen, lower alkoxy, aryl-lower alkoxy;

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

b'') Compound of formula I, V, VI, VII, V', VI', VII', VIa, Vib or VII'' that is a matrix metalloproteinase inhibitor.

c") one of the compounds disclosed in published international patent applications Nos. WO 98/14424, WO 97/22587 and EP 606046 in particular the compound N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate;
or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt thereof.

Compounds of formula I, II, III, IV, V, VI and VII and their synthesis are described in published international patent applications Nos. WO 98/14424, WO 97/22587 and EP 606046, the teachings of which are incorporated herein by reference.

The agents of the invention, i.e. the MMP inhibitors of formula I and pharmaceutically acceptable salts and prodrug derivatives, are preferably used in the form of pharmaceutical preparations that contain the relevant therapeutically effective amount of active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.

The MMP inhibitor pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic), or compositions for topical administration,

Preferably, the MMP inhibitor pharmaceutical compositions are adapted to oral administration.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, etc.

The dosage of the Agents of the invention may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, and/or sex, age, weight and individual condition of the subject to be treated.

The agents of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously. Such fluids are preferably aqueous isotonic solutions or suspensions that can be prepared before use, for example from lyophilised preparations that contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.

Suitable oral forms are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminium

silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid, or its sodium salt, or effervescent mixtures; and/or e) adsorbents, colorants, flavours and sweeteners. Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable formulations for topical application, e.g. to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels, or sprayable formulations, for example, for delivery by aerosol or the like. Such topical formulations typically contain from about 0.1 up to about 50% by weight, preferably from about 1 up to about 20% by weight, of MMP inhibitor.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.

Examples

Example 1

Tablets each containing 50mg of N-hydroxy-2 (R)-[[4-methoxyphenylsulfonyl](3-picolyl)-amino]-3-methylbutanamide hydrochloride can be prepared as follows:

Composition (10,000 tablets)

Active ingredient	500.0g
Lactose	500.0g
Potato starch	325.0g
Gelatin	8.0g
Talc	60.0g
Magnesium stearate	10.0g
Silicon dioxide (finely divided)	20.0g
Ethanol	q.s

The active ingredient is mixed with the lactose and 292g of potato starch, and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a sieve.

After the granules have dried, the remainder of the potato starch, the magnesium stearate and the silicon dioxide are admixed and the mixture compressed to give tablets each weighing 145.0mg and containing 50.0mg of active ingredient, which can, if desired, be provided with breaking grooves to enable the dosage to be more freely adjusted.

Example 2

Preparation of 3000 capsules each containing 25mg of the active ingredient, for example, N-hydroxy-2 (R)-[[4-methoxyphenylsulfonyl](3-picolyl)-amino]-3-methylbutanamide hydrochloride:

Active ingredient	75.0g
Lactose	750.0g
Avicel PH 102	325.0
(microcrystalline cellulose)	
Polyplasdone XL	30.0g
(polyvinylpyrrolidone)	
Purified water	q.s
Magnesium stearate	9.0g

The active ingredient is passed through a No. 30 hand screen.

The active ingredient, lactose, Avicel PH 102 and Polyplasdone XL are blended for 15 minutes in a mixer. The blend is granulated with sufficient water (about 500mL), dried in an oven at 35°C overnight, and passed through a No. 20 screen.

Magnesium stearate is padded through a No. 20 screen, added to the granulation mixture, and the mixture is blended for 5 minutes in a mixer. The blend is encapsulated in No. 0 hard gelatin capsules each containing and amount of the blend equivalent to 25mg of the active ingredient.

Example 3

Materials and Methods

Cell culture and reagents

Three human pancreatic cancer cell lines are used in this study. Panc-1 and Suit-2 are generously provided by Dr. Iguchi (National Kyushu Cancer Center, Fukuoka, Japan), Hs766T is obtained from American type culture collection (Rockville, MD). Cells are maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma Chemical Co. St.

Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), streptomycin (100µg/ml), and penicillin (100 U/ml) at 37°C with humidified 90% air and 10% CO₂. The number of cells is counted with a particle distribution counter, CDA500 (Sysmex, Kobe, Japan). The MMP inhibitor N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl –butaneamide hydrochloride) monohydrate, is kindly provided by Novartis Pharma, K.K., Japan.

Irradiation

The cells are irradiated with doses of 3, 5, or 10 Gy at room temperature using a ¹³⁷Cs source (Gamma Cell 40, Atomic Energy of Canada Ltd., Ontario, Canada) delivering 1.0 Gy/min.

Cell proliferation assay

Cell proliferation is evaluated by measuring the fluorescence intensity of propidium iodide (PI) as described previously by Zhang et al.(Cancer Lett., 142: 129-137, 1999) with minor modifications. Briefly, cells are seeded in 24-well plates at a density of 3×10^4 cells per well. After overnight cultivation, cells are irradiated and cultured for 4 days. PI (30µM) and digitonin (600µM) are added to each well to label all nuclei of the cells with PI. Fluorescence intensity corresponding to total cells in each well is measured by a multi-well plate-reader, CYTOFLUOR II (PerSeptive Biosystems Inc., Framingham, MA, USA) with 530-nm excitation and 645-nm emission filters. The cell proliferation rate is calculated as the proportion of fluorescence intensity of each well at the time point indicated in the text to that at the day of irradiation.

Migration assay

Migration of pancreatic cancer cells through 8µM pores is assessed using the Transwell cell culture chamber (6.5 mm diameter, Corning Costar, Tokyo, Japan) as described by sato et al and Maehara et al (Cancer, 91: 496-504, 2001; Br. J. Cancer, 84: 864-873,

2001). Cells at a density of 1×10^4 are seeded in the upper chambers with 100 μ l of medium supplemented with 10% FBS. Same media of 600 μ l are placed in the lower wells. After seeding, the cells are subjected to irradiation and then cultured for 24 h. The filter membranes are removed and fixed with 70% ethanol and stained with hematoxylin and eosin (H&E). The number of cells that had migrated to the lower surface of the filter membrane is counted in five random fields under a light microscope.

Matrigel invasion assay

Invasion of pancreatic cancer cells is measured by the invasion of cells through Matrigel-coated transwell inserts (Becton Dickinson, Franklin Lakes, NJ, USA) (Sato et al and Machara et al *ibid*).

Briefly, transwell inserts with 8 μ m pore are coated with Matrigel (40 μ g/well, Becton Dickinson, Bedford, MA, USA). Five hundred μ l of cell suspension (1×10^5 /ml) are added to the upper chambers. Same media of 750 μ l are placed in the lower wells. Thereafter, the cells are irradiated and incubated for 24 h. Cells that have invaded to lower surface of the Matrigel-coated membrane are fixed with 70% ethanol, stained with H&E, and counted in five random fields under a light microscope.

Gelatin zymography

The conditioned medium either from non-irradiated or irradiated Panc-1 cells is concentrated to 10-fold with Centricon-10 (Amico, Beverly, MA, USA). Samples are added to each lane and subjected to 10% SDS-polyacrylamide gel electrophoresis, using 10% polyacrylamide gel containing 1 mg/ml gelatin. After electrophoresis, the gel is washed in 2.5% Triton X-100, and incubated in 50 mM Tris-HCl buffer (pH8.0) containing 0.5 mM CaCl_2 and 1 mM ZnCl_2 for 20 hr at 37°C. The gel is stained with 1% Coomassie Brilliant Blue R-250 and destained with destaining buffer (5% acetic acid and 10% methanol).

Western blotting

The proteins (80 µg/lane) from the soluble fraction of Panc-1 cells are fractionated by 10% SDS–polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). The membrane is incubated with 1:500 dilutions of polyclonal antibody for human uPA (urokinase–type plasminogen activator, Santa Cruz Biotechnology, CA, USA), and then probed with anti–goat IgG conjugated with horseradish peroxides (Santa Cruz Biotechnology, CA, USA). Immunoblots are detected by the enhanced chemiluminescence (Amersham International, Buckinghamshire, UK).

Statistical analysis

Statistical analyses are performed by using ANOVA and unpaired Student's *t* test. All statistics are performed on two–sided test. $P < 0.05$ is considered as significant. Each experiment is repeated at least three times.

Results

Irradiation inhibits proliferation of pancreatic cancer cells

First, we examine the proliferation of pancreatic cancer cells after irradiation. Irradiation suppressed the proliferation of Panc-1 cells in a dose-dependent manner, and an almost complete inhibition is observed at a dose of 10 Gy. Similar results are obtained in Suit-2 at the same dose range. In Hs766T cells, however, while dose reached to 5 Gy, radiation had already entirely inhibited the cell growth.

Irradiation promotes invasive potential but inhibits migration ability in a subset of pancreatic cancer cells

To determine the effect of radiation on cell motility, we analyse the migration of human pancreatic cancer cells before and after irradiation using the Transwell cell migration assay. Compared with untreated controls, Panc-1 and Suit-2 cells irradiated at doses of 3,

5, and 10 Gy show significantly lower numbers of migrated cells. There is no significant change in migration potential after irradiation in Hs766T cells, which show a relatively low basal migration activity.

We next examine changes in the invasive potentials of pancreatic cancer cells after irradiation using the Matrigel invasion assay. In contrast to the decline in migration ability, invasive potentials in both Panc-1 and Suit-2 cells are significantly increased after irradiation at doses of 3, 5, and 10 Gy. This increase in invasive potential appears to be dose-dependent. Remarkably, the average number of invaded cells in Panc-1 is increased by more than 2-fold after irradiation at 10 Gy. We find no significant change in invasive potential in irradiated Hs766T cells.

Irradiation increases MMP-2 activity

To determine the role of gelatinases in the radiation-induced changes in invasive potential, we examine MMPs activity in Panc-1 cells before and after irradiation. Cells are incubated 24 h after irradiation and the conditioned medium is subjected to the gelatin zymography. Untreated Panc-1 cells secrete both latent and active forms of MMP-2 (72 kDa and 62kDa gelatinases). After irradiation, MMP-2 activity of either latent or activated type is significantly increased, thus suggesting that the increased MMP-2 activity may play an important role in the enhanced invasiveness after irradiation.

An MMP inhibitor blocks the radiation-enhanced invasion of pancreatic cancer cells

Finally, we test whether a synthetic MMP inhibitor, N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate, could prevent the radiation-enhanced invasiveness. N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate is added to invasion chambers at final concentrations of 1, 5, and 10 μ M just before irradiation. After irradiation at 5 Gy, the number of invaded cells in Panc-1 increase from 14.6 cells/ field to 24.4 cells /field, whereas concomitant treatment with N-


hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate at concentrations of 5 and 10 μ M significantly block the increase in invaded cells after irradiation. Treatment with N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate does not affect the growth and viability of Panc-1 cells at concentrations up to 10 μ M. Furthermore, gelatin zymography reveals that treatment with N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate at 5 μ M markedly decreases the active type MMP-2 without affecting the enzymatic activity of latent type MMP-2.

Expression of urokinase-type plasminogen activator (uPA) decreases after irradiation

To determine the possible involvement of uPA in the changes in cell motility after irradiation, we examine the expression of uPA in Panc-1 cells by Western blotting. The uPA expression in cell lysate that represents the constituent portion of uPA is suppressed by irradiation.


Claims

1. A method of treating cancer that can be treated with radiotherapy in a subject in need of such treatment which comprises radiotherapy in combination with administering to the subject an effective amount of a matrix metalloproteinase inhibitor of the formula I



(i) Wherein

A represents substituent of formula II or III;



Formula II

wherein


R represents hydrogen, lower alkyl, aryl-lower alkyl, aryl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, (oxa or thia)-cycloalkyl, [(oxa or thia)-cycloalkyl]-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower

alkyl, (N-lower alkyl-piperazino or N-aryl- lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl;

R₃ represents aryl that may be unsubstituted or substituted by R₄ and R₅;

R₄ or R₅ represents independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano, oxy-C2-C3-alkylene, 1- or 2-naphthyl; or R₄ and R₅ together on adjacent carbon atoms represent lower alkylenedioxy;

n represents an integer from 1 to 5;



Formula III


Wherein

R₆ is C₃₋₁₂ alkyl, C₃₋₁₂ alkenyl, C₃₋₇(optionally hydroxy-, C₁₋₆ alkoxy-, amino-, or C₁₋₆ alkylamino- substituted) cycloalkyl, C₅₋₁₄ aryl, or C₅₋₁₄ aryl(C₁₋₆ alkyl), wherein aryl groups are optionally substituted by hydroxy-, C₁₋₆ alkyl-, C₁₋₆ alkoxy-, amino-, halo- or cyano-;

R₇ is C₁₋₁₀ (optionally hydroxy- or C₁₋₆alkoxy- amino-, C₁₋₆ alkylamino-, thiol-, C₁₋₆ alkylmercapto- or protected hydroxy-, amino- or thiol- substituted) alkyl, C₆₋₁₄ (optionally hydroxy-, C₆₋₁₄aryloxy-, or C₁₋₆alkoxy-, amino-, C₁₋₆ alkylamino-, halo-, or cyano-substituted)aryl, or indolylmethyl;

R_8 is methyl, pyridyl, or a substituent of formula X-Y- wherein X is morpholino, pyridyl or aryl, and Y is C_{1-12} alkylene in which up to four of the methylene ($-CH_2-$) units are optionally replaced with $-CO-$, $-NH-$, $-SO_2-$ or $-O-$;

R_1 is hydrogen, lower alkyl, aryl, aryl-lower alkyl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, cycloalkyl-cycloalkyl, aryl-lower alkyl-lower cycloalkyl, lower alkyl-cycloalkyl, lower alkoxy-lower alkyl-cycloalkyl, aryl-cycloalkyl, cycloalkyl-lower alkyl-cycloalkyl, halo-lower alkyl-cycloalkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl, N-lower alkylpiperidyl or a substituent of formula IV



Formula IV

wherein

z is 1, 2, 3 or 4;

m is 0, 1, 2 or 3;

each R_9 is

independently H, C_{1-10} (optionally hydroxy-, C_{1-6} alkoxy-, amino-, C_{1-6} alkylamino-, thiol-, C_{1-6} alkylmercapto- or protected hydroxy, amino or thiol substituted) alkyl, C_{2-6} alkenyl, C_{6-14} (optionally hydroxy-, C_{1-6} alkoxy-, amino-, C_{1-6} alkylamino-, halo- or cyano-substituted) aryl, or C_{6-14} (aryl) C_{1-6} alkyl;

D is hydrogen, C₁₋₁₀ alkyl, C₆₋₁₄ aryl, C₆₋₁₄ aryl(C₁₋₆ alkyl), (C₆₋₁₄ aryl)carbonyl, or (C₁₋₁₀ alkyl)carbonyl;

R₂ is hydrogen or lower alkyl,

(ii) or wherein

R (of formula II under (a)) and R₁ together with the chain to which they are attached form a 1,2,3,4-tetrahydro-isoquinoline, piperidine, oxazolidine, thiazolidine or pyrrolidine ring, each unsubstituted or substituted by lower alkyl; and

R₃ and R₂ have meaning as defined under (i);

(iii) or wherein

R₁ and R₂ together with the carbon atom to which they are attached form a ring system selected from lowercycloalkane which is unsubstituted or substituted by lower alkyl, oxa-cyclohexane, thia-cyclohexane, indane, tetralin, piperidine or piperidine substituted on nitrogen by acyl, lower alkyl, aryl-lower alkyl, (carboxy, esterified or amidated carboxy)-lower alkyl or by lower alkylsulfonyl; and

R₃ and R meaning as defined under (i);

or a pharmaceutically acceptable prodrug derivative thereof; or a pharmaceutically acceptable salt thereof.

2. Use of a compound of formula I as defined in claim 1 (or pharmaceutically acceptable salt or prodrug ester thereof) for the preparation of a medicament, for use in combination with radiotherapy for the treatment of cancer which can be treated with radiotherapy.
3. Use of a compound of formula I as defined in claim 1 (or pharmaceutically acceptable salt or prodrug ester thereof) in combination with radiotherapy for the treatment of cancer which can be treated with radiotherapy.
4. A package comprising a compound of formula I as defined in claim 1 (or pharmaceutically acceptable salt or prodrug ester thereof) together with instructions for use in combination with radiotherapy in the treatment of carcinoma.
5. A method according to claim 1, in which the compound of formula I is one of the compounds disclosed in published international patent applications Nos. WO 98/14424, WO 97/22587 and EP 606046, or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt thereof.
6. A method according to claim 1, in which the compound of formula I is N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl -butaneamide hydrochloride) monohydrate, or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt thereof.
7. A method according to claim 1 in which the compound of formula I, or a pharmacologically acceptable salt or prodrug ester, is in the form of a enteral composition.
8. All new methods, compositions and uses as hereinbefore described with reference to the examples.